Health Care & Hospital Law
Apr. 15, 2015
Shaping the emerging biosimilars industry
It is not often we see the creation of a new industry that has the potential to impact people's lives to the degree that biosimilars may. By Siegmund Gutman and Joshua Kopple
It is not often we see the creation of a new industry that has the potential to impact people's lives to the degree that biosimilars may. Several significant developments to the emerging biosimilars industry have occurred over the past year. In March 2015, the Food and Drug Administration approved the first-ever U.S. biosimilar, Zarxio, by Sandoz. In an effort to address the many questions surrounding biosimilars, the FDA...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In